EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations

Tal Etan, Lior Cohen, Yael Bar, Yasmin Leshem, Shir Lerner, Irina Stepansky, Iris Shiran, Amir Sonnenblick, Shlomit Strulov Shachar

Breast Cancer Research and Treatment · 2026-06 · 217 (3)

DOI: 10.1007/s10549-026-08006-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 22.06.2026. Verfasst von Tal Etan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute, Tel Aviv Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Germ-Line Mutation, Antineoplastic Combined Chemotherapy Protocols, BRCA1 Protein. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The addition of pembrolizumab (KN522) to neoadjuvant doxorubicin, cyclophosphamide (AC), carboplatin and paclitaxel (TC) has significantly improved survival, albeit with increased toxicity. This study aims to evaluate the effectiveness and toxicity of KN522 and to decouple the relative contributions of germline BRCA mutations (gBRCAmut) and pembrolizumab addition.

Methods

A retrospective analysis of patients with stage II–III triple negative breast cancer, treated at a single tertiary medical center with either KN522 or ACTC.

Results

Among 127 patients, four cohorts were evaluated: (1) KN522-gBRCAmut ( n = 26), (2) KN522-BRCA wildtype ( n = 53), (3) ACTC-gBRCAmut ( n = 18), (4) ACTC-BRCA wildtype ( n = 30). The KN522-gBRCAmut cohort achieved a remarkable pCR rate of 92.3%, compared to 60.4%, 55.6% and 36.7% in cohorts (2), (3) and (4) respectively. Multivariable analysis identified the KN522 protocol (OR 3.69, 95% CI 1.66–8.20; p = 0.001) and gBRCAmut status (OR 3.78, 95% CI 1.57–9.12; p = 0.003) as independent predictors of pCR. Achieving pCR was associated with improved event-free and overall survival (OS) in univariate analyses. In multivariable models, however, pCR remained a significant independent predictor of OS only (HR = 0.15, 95% CI: 0.03–0.72, p = 0.018). KN522 was associated with higher hospitalization rates (40.5% vs. 14.6%, p = 0.003) and more neutropenic fever (NF) events (32.9% vs. 2.1%, p < 0.001), likely due to lower G-CSF prophylaxis during the AC part of the KN522 protocol (21.5% vs. 68.8%, p < 0.001).

Conclusions

In this analysis, gBRCAmut carriers treated with KN522 achieved remarkably high pCR rates. The observed 40% hospitalizations, primarily due to NF, highlights the need for supportive care optimization, including G-CSF consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsGerm-Line MutationAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinImmunotherapyHumansFemaleNeoadjuvant TherapyMiddle AgedAntibodies, Monoclonal, HumanizedAgedAdultRetrospective StudiesTreatment OutcomePaclitaxelNeoplasm StagingCarboplatinDoxorubicinCyclophosphamide

Stichwörter der Autor:innen

BRCAG-CSFImmunotherapyNeutropenic feverTriple-negative breast cancer

Substanzen

Antibodies, Monoclonal, HumanizedBRCA1 ProteinBRCA2 ProteinpembrolizumabPaclitaxelCarboplatinDoxorubicinBRCA2 protein, humanBRCA1 protein, humanCyclophosphamide

Autor:innen und Institutionen

  • Oncology Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Sigma Statistics Ltd., Statistical Consulting Services, Tel Aviv, Israel.
  • Oncology Institute, Tel Aviv Medical Center, Tel Aviv, Israel. shlomits5@tauex.tau.ac.il.
  • Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. shlomits5@tauex.tau.ac.il.

Förderung

  • Tel Aviv University

Zitieren

APA

Etan, T., Cohen, L., Bar, Y., Leshem, Y., Lerner, S., Stepansky, I., Shiran, I., Sonnenblick, A., & Shachar, S. S. (2026). Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations. Breast Cancer Research and Treatment, 217(3). https://doi.org/10.1007/s10549-026-08006-3

Vancouver

Etan T, Cohen L, Bar Y, Leshem Y, Lerner S, Stepansky I, et al. Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations. Breast Cancer Research and Treatment. 2026;217(3). doi:10.1007/s10549-026-08006-3

BibTeX
@article{Etan2026,
  author = {Etan, Tal and Cohen, Lior and Bar, Yael and Leshem, Yasmin and Lerner, Shir and Stepansky, Irina and Shiran, Iris and Sonnenblick, Amir and Shachar, Shlomit Strulov},
  title = {Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {217},
  number = {3},
  doi = {10.1007/s10549-026-08006-3}
}
Kostenlos starten →